Abstract
For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Differe......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
